Beam Therapeutics Inc. (NASDAQ:BEAM) Stock Has Consensus Target Price of $46.90 According to Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Beam Therapeutics, with eight buys, one strong buy, two holds and one sell. The average 12-month price target is $46.90, though targets vary widely, including Wedbush’s reduction to $28 and Canaccord’s increase to $79.
• Beam’s stock opened at $27.23, versus a 12-month range of $20.23 to $38.26, while the company continues to post significant losses. Its latest quarterly results missed expectations, with an EPS loss of $1.18 and revenue of just $0.49 million.
• Institutional investors own 99.68% of the shares, with Alphabet among the investors establishing a new position. CEO John Evans sold 25,000 shares worth approximately $589,250, reducing his stake by 2.33%.

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $46.90.

BEAM has been the topic of a number of recent research reports. Wedbush reduced their target price on shares of Beam Therapeutics from $65.00 to $28.00 and set an "outperform" rating on the stock in a report on Wednesday. HC Wainwright reiterated a "buy" rating on shares of Beam Therapeutics in a report on Tuesday. Canaccord Genuity Group boosted their price objective on shares of Beam Therapeutics from $78.00 to $79.00 and gave the company a "buy" rating in a research report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of Beam Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Beam Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of the firm's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total value of $589,250.00. Following the sale, the chief executive officer directly owned 1,047,205 shares of the company's stock, valued at approximately $24,682,621.85. This trade represents a 2.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Alphabet Inc. purchased a new stake in Beam Therapeutics in the second quarter valued at approximately $11,037,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Beam Therapeutics during the second quarter worth approximately $1,309,000. Canal Insurance CO purchased a new position in Beam Therapeutics during the first quarter worth approximately $953,000. Legal & General Group Plc acquired a new position in shares of Beam Therapeutics in the 2nd quarter valued at $2,717,000. Finally, Jupiter Topco LLC acquired a new position in shares of Beam Therapeutics in the 2nd quarter valued at $3,259,000. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

Beam Therapeutics Price Performance

BEAM stock opened at $27.23 on Friday. The firm has a 50 day moving average of $25.93 and a 200-day moving average of $28.19. Beam Therapeutics has a 12-month low of $20.23 and a 12-month high of $38.26. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The company has a market cap of $2.81 billion, a price-to-earnings ratio of -31.66 and a beta of 2.20.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million for the quarter, compared to analyst estimates of $16.37 million. Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%. The company's quarterly revenue was down 94.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.00) EPS. As a group, equities analysts expect that Beam Therapeutics will post -4.49 EPS for the current fiscal year.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Clinical optimism remains a potential support. Beam reviewed initial Phase 1/2 data for BEAM-301 in glycogen storage disease type 1a, keeping investor attention on the company’s base-editing pipeline and future milestone potential. Beam Therapeutics reviews initial BEAM-301 data
• Positive Sentiment: Citi initiated or reiterated a Buy view on Beam, while broader healthcare commentary also identified BEAM among attractive stocks. This reinforces the bullish long-term case centered on gene editing and potential pipeline catalysts. Beam Therapeutics gets a Buy from Citi
• Positive Sentiment: Shares previously gained 15.6% on above-average volume, suggesting strong short-term interest. However, the accompanying analysis cautioned that recent earnings-estimate trends may not sustain the rally. Beam Therapeutics moves 15.6% higher
• Neutral Sentiment: Beam crossed above its 200-day moving average, a potentially constructive technical signal, but the report tied the move to an analyst downgrade, limiting its significance. Beam crosses above its 200-day moving average
• Negative Sentiment: Wedbush cut its price target, adding pressure to the stock after its recent advance. The downgrade signals more cautious near-term expectations even as other analysts remain constructive. Wedbush cuts Beam Therapeutics price target
• Negative Sentiment: HC Wainwright retained a Buy rating but lowered most 2026–2029 EPS forecasts, including FY2026 to a loss of $4.67 per share and FY2027 to a loss of $5.23. The revisions highlight continued heavy losses and delayed profitability; FY2030 was modestly improved to a $1.48 loss. HC Wainwright earnings estimate revisions

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company's platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam's pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.